Johnson & Johnson: RYBREVANT Plus Standard of Care Approved in the U.S. as First and Only Targeted Regimen to Cut Risk of Disease Progression by More Than Half in Secondline EGFR-Mutated Advanced Lung Cancer
September 21, 2024
September 21, 2024
RARITAN, New Jersey, Sept. 21 (TNSres) -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release on Sept. 19, 2024:
* * *
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT this year, with four indications overall
* * *
Johnson & Johnson (NYSE: JNJ) announced today that the . . .
* * *
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT this year, with four indications overall
* * *
Johnson & Johnson (NYSE: JNJ) announced today that the . . .